Table 3 |
|||
|
Treatment outcomes at D28 |
|||
| Treatment outcome (No, %) [95 CI] |
|||
|
|
|||
| Rural area (n = 62) |
Urban area (n = 55) |
Total (n = 117) |
|
|
|
|||
| ETF |
0 (0%) [0–6%] |
0 (0%) [0–6%] |
0 (0%) [0–3%] |
| LCF |
|||
| - Recrudescence |
9 (15%) [7–26%] |
11 (20%) [10–33%] |
20 (17%) [11–25%] |
| - New infection |
5 (8%) [3–18%] |
7 (13%) [5–24%] |
12 (10%) [5–17%] |
| - No genotyping results |
2 (3%) [0–11%] |
2 (4%) [0–13%] |
4 (3%) [1–9%] |
| LPF |
|||
| - Recrudescence |
14 (23%) [13–35%] |
5 (9%) [3–20%] |
19 (16%) [10–24%] |
| - New infection |
17 (27%) [17–40%] |
14 (25%) [15–39%] |
31 (26%) [19–35%] |
| - No genotyping results |
2 (3%) [0–11%] |
1 (2%) [0–10%] |
3 (3%) [1–7%] |
| ACPR |
13 (21%) [12–33%] |
15 (27%) [16–41%] |
28 (24%) [17–33%] |
| ACPR (PCR-corrected) |
35 (56%) [43–69%] |
36 (65%) [51–78%] |
71 (61%) [51–70%] |
|
|
|||
|
Mandi et al. Malaria Journal 2008 7:58 doi:10.1186/1475-2875-7-58 |
|||
